

Aurobindo recalls epilepsy drug lot in US

25 November 2014 | Regulatory | By BioSpectrum Bureau

Aurobindo recalls epilepsy drug lot in US



Singapore: India-based Aurobindo Pharma in the US is recalling Gabapentin capsules, USP 300 mg 100-count bottles, at consumer level due to possible stashes of some empty capsules.

USFDA has advised that empty capsules could result in missed dose(s) of gabapentin resulting in adverse health consequences that could range from no effect, short term reduction in efficacy, short term withdrawal effect, or status epilepticus (long period seizures) that could be life-threatening.

Gabapentin is used as in the treatment of epilepsy and for the management of postherpetic neuralgia (pain after shingles).